ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 23, 2023 16:05 ET
|
ADMA Biologics, Inc.
4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase FY 2023 Total Revenue Expected to Exceed $210 Million ...
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
March 16, 2023 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
February 08, 2023 07:00 ET
|
ADMA Biologics, Inc.
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 ...
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
January 17, 2023 07:00 ET
|
ADMA Biologics, Inc.
Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately...
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
December 13, 2022 07:00 ET
|
ADMA Biologics, Inc.
FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life Provides for...
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 09, 2022 16:05 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
December 07, 2022 08:45 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Proposed Public Offering of Common Stock
December 06, 2022 16:05 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
December 06, 2022 16:01 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022 16:05 ET
|
ADMA Biologics, Inc.
3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145...